Strategies for immunotherapy of cancer.

[1]  Cécile Gouttefangeas,et al.  Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach , 2000, European journal of immunology.

[2]  P M Kloetzel,et al.  Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site1 , 2000, The Journal of Immunology.

[3]  P. Krammer.  CD95(APO-1/Fas)-mediated apoptosis: live and let die. , 1999, Advances in immunology.

[4]  W. Kast,et al.  Successful immunotherapy of an intraocular tumor in mice. , 1999, Cancer research.

[5]  R. Offringa,et al.  Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.

[6]  J. Shabanowitz,et al.  Mass‐spectrometric evaluation of HLA‐A*0201‐associated peptides identifies dominant naturally processed forms of CTL epitopes from MART‐1 and gp100 , 1999 .

[7]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[8]  P. Schrier,et al.  Interleukin‐2‐induced, melanoma‐specific T cells recognize camel, an unexpected translation product of LAGE‐1 , 1999, International journal of cancer.

[9]  A Sette,et al.  Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. , 1999, Journal of immunology.

[10]  F. Marincola,et al.  Cancer therapy using a self-replicating RNA vaccine , 1999, Nature Medicine.

[11]  H. Bien,et al.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.

[12]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[13]  H. Rammensee,et al.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.

[14]  C. Rooney,et al.  Autoimmune disease induced by dendritic cell immunization against leukemia. , 1999, Leukemia research.

[15]  D. Taub,et al.  Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand , 1999 .

[16]  C. Takahashi,et al.  Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. , 1999, Journal of immunology.

[17]  R. Levy,et al.  DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. , 1999, Journal of immunology.

[18]  R. Verdijk,et al.  Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. , 1999, Blood.

[19]  E. Engleman,et al.  Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. , 1999, Blood.

[20]  C. Kurts,et al.  Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells , 1999, Nature.

[21]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Andino,et al.  Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen , 1999, Nature.

[23]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[24]  J. Shabanowitz,et al.  Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[25]  Matteo Bellone,et al.  Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.

[26]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[27]  Ferry Ossendorp,et al.  CD4 T Cells and Their Role in Antitumor Immune Responses , 1999, The Journal of experimental medicine.

[28]  F. Sallusto,et al.  Mobilizing Dendritic Cells for Tolerance, Priming, and Chronic Inflammation , 1999, The Journal of experimental medicine.

[29]  W. Baumeister,et al.  A giant protease with potential to substitute for some functions of the proteasome. , 1999, Science.

[30]  F. Guadagni,et al.  Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. , 1999, Cancer research.

[31]  R. Brown,et al.  p53-oriented cancer therapies: current progress. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  R. Levy,et al.  Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Ingo Schmitz,et al.  The Role of c-FLIP in Modulation of CD95-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[34]  B. Stockinger,et al.  DNA Vaccination:  Transfection and Activation of Dendritic Cells as Key Events for Immunity , 1999, The Journal of experimental medicine.

[35]  I. Frazer.  The current status of development of prophylactic vaccines against Human Papillomavirus infection , 1999 .

[36]  S. Rosenberg,et al.  Developing recombinant and synthetic vaccines for the treatment of melanoma. , 1999, Current opinion in oncology.

[37]  J. Marshall,et al.  Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. Rammensee,et al.  Alloreactivity as a source of high avidity peptide-specific human CTL. , 1999, Journal of immunology.

[39]  T. Starzl,et al.  Antigen localization and migration in immunity and tolerance. , 1998, The New England journal of medicine.

[40]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[41]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[42]  Alan J. Barrett,et al.  An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation , 1998, Nature.

[43]  P. Brossart,et al.  Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. , 1998, Cancer research.

[44]  B. Chain,et al.  In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Loenen.  Editorial overview: CD27 and (TNFR) relatives in the immune system: their role in health and disease , 1998 .

[46]  R. V. van Lier,et al.  Control of lymphocyte function through CD27-CD70 interactions. , 1998, Seminars in immunology.

[47]  F. Garrido,et al.  HLA and cancer: from research to clinical impact. , 1998, Immunology today.

[48]  Toshiki Watanabe,et al.  CD30: expression and function in health and disease. , 1998, Seminars in immunology.

[49]  R. Offringa,et al.  CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. , 1998, Seminars in immunology.

[50]  R. Noelle,et al.  CD40 and its crucial role as a member of the TNFR family. , 1998, Seminars in immunology.

[51]  J. Sogn.  Tumor immunology: the glass is half full. , 1998, Immunity.

[52]  B. Kwon,et al.  Role of 4-1BB in immune responses. , 1998, Seminars in immunology.

[53]  J. Reimann,et al.  Similar as well as distinct MHC class I‐binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen , 1998, European journal of immunology.

[54]  J. Borst,et al.  Tumor necrosis factor receptor family members in the immune system. , 1998, Seminars in immunology.

[55]  F. Brasseur,et al.  Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. , 1998, Tissue antigens.

[56]  M. Croft,et al.  OX-40: life beyond the effector T cell stage. , 1998, Seminars in immunology.

[57]  H. Rammensee,et al.  Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome‐dependent and ‐independent proteolytic activities , 1998, European journal of immunology.

[58]  G. Nabel,et al.  Regulation of the proinflammatory effects of Fas ligand (CD95L). , 1998, Science.

[59]  J. Fagerberg,et al.  Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen , 1998, Cancer Immunology, Immunotherapy.

[60]  M. Hollingsworth,et al.  CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. , 1998, Journal of immunology.

[61]  P. Ciborowski,et al.  Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. , 1998, Cancer research.

[62]  J. Altman,et al.  Characteristics of virus-specific CD8(+) T cells in the liver during the control and resolution phases of influenza pneumonia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[64]  A. Hamad,et al.  Potent T Cell Activation with Dimeric Peptide–Major Histocompatibility Complex Class II Ligand: The Role of CD4 Coreceptor , 1998, The Journal of experimental medicine.

[65]  L. Owen-Schaub,et al.  Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis , 1998, The Journal of experimental medicine.

[66]  P. Kalinski,et al.  High-level IL-12 production by human dendritic cells requires two signals. , 1998, International immunology.

[67]  S. Rosenberg,et al.  Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. , 1998, Cancer research.

[68]  K. Irvine,et al.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. , 1998, Journal of immunology.

[69]  P. Kourilsky,et al.  In vitro induction of naive cytotoxic T lymphocytes with complexes of peptide and recombinant MHC class I molecules coated onto beads: role of TCR/ligand density , 1998, European journal of immunology.

[70]  H. Engelmann,et al.  CD40 induces resistance to TNF‐mediated apoptosis in a fibroblast cell line , 1998, European Journal of Immunology.

[71]  Loise M. Francisco,et al.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.

[72]  J. Tschopp,et al.  FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. , 1998, Journal of immunology.

[73]  Loise M. Francisco,et al.  Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.

[74]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[75]  R. Zinkernagel,et al.  Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. , 1998, Immunity.

[76]  A. Trautmann,et al.  CD8 expression allows T cell signaling by monomeric peptide-MHC complexes. , 1998, Immunity.

[77]  F. Garrido,et al.  Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line , 1998, Cancer Immunology, Immunotherapy.

[78]  J. Altman,et al.  Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. , 1998, Immunity.

[79]  B. Gil-Torregrosa,et al.  Major Histocompatibility Complex Class I Viral Antigen Processing in the Secretory Pathway Defined by the trans-Golgi Network Protease Furin , 1998, The Journal of experimental medicine.

[80]  G. Ogg,et al.  High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo , 1998, The Journal of experimental medicine.

[81]  P. Kloetzel,et al.  The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.

[82]  R. Germain,et al.  Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization , 1998, The Journal of experimental medicine.

[83]  B. Longenecker,et al.  Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. , 1998, Cancer research.

[84]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[85]  D. Srivastava,et al.  Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .

[86]  G. Klein,et al.  Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. , 1998, Journal of immunology.

[87]  J. Gunn,et al.  Dendritic cells require maturation via CD40 to generate protective antitumor immunity. , 1998, Journal of immunology.

[88]  Millard,et al.  PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells , 1998, British journal of haematology.

[89]  A. Diab,et al.  Allogeneic cell therapy for a murine mammary carcinoma. , 1998, Cancer research.

[90]  J. Allison,et al.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[91]  T. Elliott,et al.  Glycan-regulated Antigen Processing of a Protein in the Endoplasmic Reticulum Can Uncover Cryptic Cytotoxic T Cell Epitopes , 1998, The Journal of experimental medicine.

[92]  M. Sadelain,et al.  Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes , 1998, The Journal of experimental medicine.

[93]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[94]  M. Sy,et al.  Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. , 1998, Cancer research.

[95]  P. Coulie,et al.  Estimation of the frequencies of anti‐MAGE‐3 cytolytic T‐lymphocyte precursors in blood from individuals without cancer , 1998, International journal of cancer.

[96]  H. Rammensee,et al.  Allo‐ and self‐restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire , 1998, European journal of immunology.

[97]  P. Casali,et al.  CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. , 1998, Immunity.

[98]  Stefan Imreh,et al.  A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IκBα with the proteasome: a new mechanism for selective inhibition of proteolysis , 1998, Nature Medicine.

[99]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[100]  C. Kurts,et al.  The Peripheral Deletion of Autoreactive CD8+ T Cells Induced by Cross-presentation of Self-antigens Involves Signaling through CD95 (Fas, Apo-1) , 1998, The Journal of experimental medicine.

[101]  R. Offringa,et al.  Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. , 1998, Cancer research.

[102]  R. Offringa,et al.  Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. , 1998, Cancer research.

[103]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[104]  P. Romero,et al.  Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. , 1998, Molecular medicine today.

[105]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[106]  C. Figdor,et al.  Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. , 1998, Cancer research.

[107]  L. Michaux,et al.  LAGE‐1, a new gene with tumor specificity , 1998, International journal of cancer.

[108]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[109]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[110]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[111]  E. Gilboa,et al.  Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells , 1998, European journal of immunology.

[112]  L. Adorini,et al.  Th1 cells induce and Th2 inhibit antigen‐dependent IL‐12 secretion by dendritic cells , 1998, European journal of immunology.

[113]  T. Mak,et al.  CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand , 1998, The Journal of experimental medicine.

[114]  D. Kufe,et al.  Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[115]  H. Rammensee,et al.  Protective Immunity Does Not Correlate with the Hierarchy of  Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides , 1998, The Journal of experimental medicine.

[116]  C. Kurts,et al.  Cross-tolerance: A Pathway for Inducing Tolerance to Peripheral Tissue Antigens , 1998, The Journal of experimental medicine.

[117]  D. Taub,et al.  Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.

[118]  R. Offringa,et al.  Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. , 1998, Journal of immunology.

[119]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  M. Mihm,et al.  Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[121]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[122]  P. Doherty,et al.  Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells , 1998, Nature.

[123]  C. Meijer,et al.  Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. , 1998, Cancer research.

[124]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[125]  Simon C Watkins,et al.  Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. , 1998, Journal of immunology.

[126]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[127]  S. Ostrand-Rosenberg,et al.  Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.

[128]  G. Ogg,et al.  Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood , 1998, Current Biology.

[129]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[130]  G. Trinchieri,et al.  Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. , 1998, The Journal of clinical investigation.

[131]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[132]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[133]  Young‐June Kim,et al.  Human 4‐1BB regulates CD28 co‐stimulation to promote Th1 cell responses , 1998, European journal of immunology.

[134]  D. Roopenian,et al.  Much ado about minor histocompatibility antigens. , 1998, Immunology today.

[135]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[136]  C. Newstead.  Assessment of risk of cancer after renal transplantation , 1998, The Lancet.

[137]  H. Rammensee,et al.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.

[138]  R. Offringa,et al.  Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. , 1998, Cancer research.

[139]  R. Burk,et al.  Natural history of cervicovaginal papillomavirus infection in young women , 1998 .

[140]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[141]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[142]  E. Raz,et al.  Gene vaccination: plasmid DNA is more than just a blueprint. , 1998, Immunology today.

[143]  C. Wilson,et al.  Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. , 1998, Journal of immunology.

[144]  J. Zeuthen,et al.  In vivo and in vitro generation of a new altered HLA phenotype in melanoma‐tumour‐cell variants expressing a single HLA‐class‐I allele , 1998, International journal of cancer.

[145]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[146]  H. Stauss,et al.  Generation of human tumor‐reactive cytotoxic T cells against peptides presented by non‐self HLA class I molecules , 1998, European journal of immunology.

[147]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.

[148]  R. Mulligan,et al.  Induction of protective anti-tumor immunity by gene-modified dendritic cells. , 1995, Journal of immunotherapy.

[149]  A. Deleo.  p53-based immunotherapy of cancer. , 1998, Critical reviews in immunology.

[150]  J. Yewdell,et al.  Strategies for tumor elimination by cytotoxic T lymphocytes. , 1998, Critical reviews in immunology.

[151]  A. Lanzavecchia,et al.  The duration of antigenic stimulation determines the fate of naive and effector T cells. , 1998, Immunity.

[152]  R. Offringa,et al.  Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[153]  C. Kurts,et al.  CD4+ T Cell Help Impairs CD8+ T Cell Deletion Induced by Cross-presentation of Self-Antigens and Favors Autoimmunity , 1997, The Journal of experimental medicine.

[154]  V. Apostolopoulos,et al.  Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. , 1997, Journal of immunology.

[155]  J. Schlom,et al.  Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[156]  S. Rosenberg,et al.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.

[157]  Z. Eshhar.  Tumor-specific T-bodies: towards clinical application , 1997, Cancer Immunology, Immunotherapy.

[158]  J. Schlom,et al.  Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. , 1997, Cancer research.

[159]  P. Bruggen,et al.  T cell defined tumor antigens , 1997 .

[160]  R. Offringa,et al.  Activation or frustration of anti-tumor responses by T-cell-based immune modulation. , 1997, Seminars in immunology.

[161]  M. Hoogeveen‐Westerveld,et al.  Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodgkin’s lymphoma , 1997, Leukemia.

[162]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[163]  G. Fleuren,et al.  Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[164]  S. Kaufmann,et al.  Alternative antigen processing pathways in anti-infective immunity. , 1997, Current opinion in immunology.

[165]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[166]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[167]  J. Cormier,et al.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. , 1997, Journal of immunotherapy.

[168]  G. Dranoff,et al.  Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. , 1997, Cancer research.

[169]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[170]  E. Goulmy.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.

[171]  J. Allison,et al.  Co-stimulation in T cell responses. , 1997, Current opinion in immunology.

[172]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[173]  M. Peter,et al.  Resistance of cultured peripheral T cells towards activation‐induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death‐inducing signaling complex , 1997, European journal of immunology.

[174]  L. Borysiewicz,et al.  Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. , 1997, Cancer research.

[175]  D. Czerwinski,et al.  Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. , 1997, Blood.

[176]  N. Leister,et al.  The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. , 1997, Journal of immunological methods.

[177]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[178]  D. Carbone,et al.  p53 as a target for anti-cancer immunotherapy. , 1997, Molecular medicine today.

[179]  J. Schlom,et al.  Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. , 1997, Vaccine.

[180]  B. Kwon,et al.  Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. , 1997, Journal of immunology.

[181]  P. Greenberg,et al.  Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. , 1997, Blood.

[182]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[183]  E. Holler,et al.  Adoptive immunotherapy with donor lymphocyte transfusions. , 1997, Current opinion in oncology.

[184]  J. Kouyoumdjian,et al.  Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. , 1997, Gut.

[185]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[186]  P. Rieu,et al.  Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. , 1997, Transplantation proceedings.

[187]  P. Coulie,et al.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.

[188]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[189]  E. Unanue,et al.  Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[190]  T. Mak,et al.  Costimulation of CD28- T lymphocytes by 4-1BB ligand. , 1997, Journal of immunology.

[191]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[192]  E. Unanue,et al.  Distinct antigen MHC class II complexes generated by separate processing pathways. , 1996, The EMBO journal.

[193]  E. Sadovnikova,et al.  Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[194]  A. Kelso,et al.  A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. , 1996, Journal of immunology.

[195]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[196]  J. Reimann,et al.  MHC class I-restricted CTL responses to exogenous antigens. , 1996, Immunity.

[197]  E. Sercarz,et al.  Harnessing self-reactivity in cancer immunotherapy. , 1996, Seminars in immunology.

[198]  C. Meijer,et al.  T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. , 1996, The Journal of general virology.

[199]  R. Offringa,et al.  Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. , 1996, Cancer research.

[200]  S. H. van der Burg,et al.  Peptide‐pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA‐A*0201‐binding peptides from the Melan‐A/MART‐1 self antigen , 1996, European journal of immunology.

[201]  P M Kloetzel,et al.  A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. , 1996, Immunity.

[202]  J. Phair,et al.  KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma , 1996, Nature Medicine.

[203]  E. Operskalski,et al.  The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma–associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission , 1996, Nature Medicine.

[204]  G. Schuler,et al.  High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10 [published erratum appears in J Exp Med 1996 Oct 1;184(4):following 1590] , 1996, The Journal of experimental medicine.

[205]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[206]  R. Offringa,et al.  Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[207]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[208]  P. Shepherd,et al.  Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. , 1996, The Journal of general virology.

[209]  R. Offringa,et al.  Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. , 1996, Journal of immunology.

[210]  R. Darnell.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[211]  S. H. van der Burg,et al.  Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.

[212]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[213]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[214]  K. Rock.  A new foreign policy: MHC class I molecules monitor the outside world. , 1996, Immunology today.

[215]  H. Griesser,et al.  Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice , 1996, Cell.

[216]  A. Sette,et al.  Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. , 1996, Cancer research.

[217]  K. Rock,et al.  Antigen processing and presentation by the class I major histocompatibility complex. , 1996, Annual review of immunology.

[218]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[219]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[220]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[221]  A. Strasser,et al.  Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.

[222]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[223]  Lubin,et al.  p53 antibodies in patients with various types of cancer: assay, identification, and characterization. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[224]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[225]  R. Henderson,et al.  Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. , 1995, Journal of immunology.

[226]  P. Kiener,et al.  Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. , 1995, Journal of immunology.

[227]  C. Figdor,et al.  Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. , 1995, Cancer research.

[228]  R. Rappuoli,et al.  Both Immunization with Protein and Recombinant Vaccinia Virus Can Stimulate CTL Specific for the E7 Protein of Human Papilloma Virus 16 in H‐2d Mice , 1995, Scandinavian journal of immunology.

[229]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[230]  D. Taub,et al.  Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. , 1995, Blood.

[231]  S. H. van der Burg,et al.  Antibodies against p53 are associated with poor prognosis of colorectal cancer. , 1995, British Journal of Cancer.

[232]  M. Bevan,et al.  Antigen presentation to cytotoxic T lymphocytes in vivo , 1995, The Journal of experimental medicine.

[233]  M. Feltkamp,et al.  Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[234]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.

[235]  T. Soussi,et al.  Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.

[236]  A. Hart,et al.  Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. , 1995, Cancer research.

[237]  Lieping Chen,et al.  Can Co‐stimulated Tumor Immunity be Therapeutically Efficacious? , 1995, Immunological reviews.

[238]  M. Mathieu,et al.  Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer , 1995, European journal of immunology.

[239]  M. Ressing,et al.  CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. , 1995, Journal of immunology.

[240]  S Miltenyi,et al.  Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[241]  F. Garrido,et al.  HLA class I antigens in human tumors. , 1995, Advances in cancer research.

[242]  J. Tschopp,et al.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.

[243]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[244]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[245]  R. Metzgar,et al.  Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. , 1994, Cancer research.

[246]  J. Allison,et al.  CD28-B7 interactions in T-cell activation. , 1994, Current opinion in immunology.

[247]  D. Longo,et al.  Inhibition of human B-cell lymphoma growth by CD40 stimulation. , 1994, Blood.

[248]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[249]  T. Eberlein,et al.  Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. , 1994, Journal of immunology.

[250]  D. Lane.  p53 and human cancers. , 1994, British medical bulletin.

[251]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[252]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[253]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[254]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[255]  H. Schreiber,et al.  A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target , 1993, The Journal of experimental medicine.

[256]  H P Koeffler,et al.  P53 mutations in human cancer. , 1993, Leukemia.

[257]  P. Krammer,et al.  Activation interferes with the APO-1 pathway in mature human T cells. , 1993, International immunology.

[258]  M. Wills,et al.  Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. , 1993, Cellular immunology.

[259]  R. Darnell,et al.  Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies , 1993, The Lancet.

[260]  C. Melief,et al.  Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. , 1992, Advances in cancer research.

[261]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[262]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[263]  R. Offringa,et al.  Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes , 1989, Cell.

[264]  D. Cassell,et al.  Linked Recognition of Helper and Cytotoxic Antigenic Determinants for the Generation of Cytotoxic T Lymphocytes a , 1988, Annals of the New York Academy of Sciences.

[265]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[266]  E. Appella,et al.  Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[267]  H. Eisen,et al.  Myeloma proteins as tumor-specific transplantation antigens. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[268]  P. Gold.  Circulating antibodies against carcinoembryonic antigens of the human digestive system , 1967 .